Steps towards understanding the Zika and Dengue link

Anti-Envelope protein [ZKA78]


Recombinant monoclonal antibody to Envelope protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the EBV transformed human B cell clone ZKA78.

 Made with Antibody Sequences licensed from Humabs Biomed SA.

UniProt Accession Number of Target Protein: Q91KX8

Alternative Name(s) of Target: E protein; ZKV E
Immunogen: mAb ZKA78 was selected from EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naïve human donors based on its ability to bind Zika virus (ZIKV) Envelope protein and to neutralize ZIKV infection.

Specificity: ZKA78 is specific for EDI/II domain of the ZIKV envelope (E) protein, and cross-reacts with the E protein from Dengue virus (DENV), which is highly homologous (also contains high sequence similarity with other flaviviruses such as yellow fever and west nile). ZKA78 showed significant binding (determined by ELISA) to the E proteins of ZIKV, DENV1-4 and the virus-like particles (VLPs) of DENV1-4. Flavivirus E proteins mediate fusion, with EDI being involved in conformational changes required for viral entry and EDII containing a fusion loop. ZIKV is a flavivirus that can be transmitted sexually, by the Aedes mosquito vector, or vertically to a developing fetus. Most cases of ZIKV infection are asymptomatic or manifest in mild symptoms, but in some cases ZIKV infection can result in Guillain-Barré Syndrome or congenital birth defects in developing fetuses.

Application Notes: ZKA78 is able to partially neutralize ZIKV infectivity (IC50 ~2863 ng/ml), and is capable of enhancing ZIKV/ infection of K526 cells via the antibody-dependent enhancement (ADE) effect. This antibody can also neutralize (IC50~ 266 ng/ml) and enhance (by ADE) DENV infection. Neutralization of ZIKV infection can be measured using a micro-neutralization FC-based assay, and binding/specificity to E protein can be studied by ELISA. DENV2-infected AG129 mice administered with ZKA78 results in death after 5 days.

Antibody first published in: Stettler et al. Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection. Science. 2016 Jul 14. pii: aaf8505.  PMID:27417494
Note on publication: Describes the isolation of a panel of antibodies derived from ZIKV-infected, DENV-naïve and ZIKV-infected, DENV-immune human donors. They were tested for their ability to bind to Zika E protein or NS1 as well as their cross-reactivity with the homologs in DENV. The capability to neutralize ZIKV infection was studied as well as the antibody-dependent enhancement effect on infection.

Author: Gilbert Tan TS

IT expert with more than 20 years experience in Multiple OS, Security, Data & Internet , Interests include AI and Big Data, Internet and multimedia. An experienced Real Estate agent, Insurance agent, and a Futures trader. I am capable of finding any answers in the world you want as long as there are reports available online for me to do my own research to bring you closest to all the unsolved mysteries in this world, because I can find all the paths to the Truth, and what the Future holds. All I need is to observe, test and probe to research on anything I want, what you need to do will take months to achieve, all I need is a few hours.​

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.